Soligenix Readies Phase 3 HyBryte FLASH2 CTCL Readout and SGX945 Progress
Soligenix enters a pivotal 2026 period with multiple anticipated clinical readouts across its pipeline, including the Phase 3 FLASH2 trial of HyBryte for CTCL. The report also highlights progress on SGX945 (dusquetide) for Behcet’s disease and reviews the company’s financial positioning ahead of key catalysts.
1. Zacks Research Report Overview
A recent analytical report highlights Soligenix’s late-stage pipeline and financial health as it approaches multiple inflection points in 2026. The review emphasizes the potential value uplift from upcoming clinical events and examines current cash reserves and burn rate.
2. Phase 3 FLASH2 Trial for HyBryte
Soligenix’s lead candidate, HyBryte, is being evaluated in the FLASH2 Phase 3 study for cutaneous T-cell lymphoma, with topline data anticipated later in the year. This trial represents the company’s most advanced program and could drive regulatory discussions if positive safety and efficacy endpoints are met.
3. SGX945 (Dusquetide) Progress
SGX945, an investigational therapy for Behcet’s disease, has advanced through early-stage studies with supportive safety profiles. The program’s next readout is expected in mid-2026, potentially opening a new rare-disease indication for the company.
4. Financial Positioning and Catalysts Timeline
Soligenix holds sufficient cash to fund operations into late 2026, supported by prior financing rounds. Key catalyst milestones, including multiple clinical readouts and potential partnering discussions, are scheduled throughout the year, offering several valuation inflection points.